BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study

(1) Introduction: BEAM is a high-dose chemotherapy (HDCT) frequently administered before autologous stem cell transplantation (ASCT) in diffuse large B-cell lymphoma (DLBCL). Bendamustine replacing BCNU (BeEAM) is similarly effective at lower toxicities. However, relapse remains the major cause of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoffel, Tanja, Bacher, Ulrike, Banz, Yara, Daskalakis, Michael, Novak, Urban, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267272/
https://www.ncbi.nlm.nih.gov/pubmed/35807041
http://dx.doi.org/10.3390/jcm11133748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267272/
https://www.ncbi.nlm.nih.gov/pubmed/35807041
http://dx.doi.org/10.3390/jcm11133748

Ejemplares similares